cyrilzakka/clinical-trials huggingface dataset:
Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude


Eligibility Criteria:
Inclusion Criteria:

* Obstructive sleep apnea syndrome, successfully on CPAP therapy
* Residence at low altitude (\<800m)
* Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.
* \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP

Exclusion Criteria:

* Sleep disorders other than OSA.
* More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.
* Any lung disease, pulmonary hypertension.
* Chronic rhinitis.
* Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
* Internal, neurologic or psychiatric disease that interfere with sleep quality.
* Previous intolerance to moderate or low altitude (\<2600m).
* Exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study
GLA:D Back Canada - a Program for Chronic and Persistent Low Back Pain

GLA:D Back is a program developed in Denmark to help people with persistent low back pain. This study will assist in contextualizing Danish content into an English version of the program.

GLA:D Back is a program developed in Denmark to help people with persistent low back pain. Unfortunately, all materials developed for the program are in Danish. In this pilot, the investigators will translate the Danish materials into English, then use them to conduct an English training session for community clinicians in Edmonton, Alberta, Canada. Interested clinicians will then implement the program in their communities and provide feedback to contextualize the program for use in English. Specifically, surveys, interviews and focus groups will be used to help fine-tune the printed content of the course (e.g. manuals), it's training materials (e.g. lectures) and processes related to REDCap data collection (e.g. surveys).

Eligibility Criteria:
Inclusion Criteria:

* Patients must have persistent low back pain of at least 1 month's duration.

Exclusion Criteria:

* Participating currently in a supervised exercise or rehabilitation program or enrolled in another interventional clinical trial.
* Patients with nerve root involvement, suspected serious pathology, unstable trauma to the spine, aspects of pregnancy or other conditions that would prevent participation or disallow trial completion within the prescribed time period.
* Persons with conditions that require a specialist consult are suspected of needing a specialist consult, or have conditions that would be aggravated or worsened if treated by the interventions in this study.
Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital

The investigators aimed to identify prognosis factors associated with in-hospital complications and assess the epidemiology, management, and outcomes of community-acquired pneumonia in a kidney transplant recipients' cohort. The investigators intend to identify each stay by a national database. Then they will be consulted by 2 clinicians to assert CAP clinical definition. After that radiographic evidence will be reviewed to validate CAP diagnoses. Then clinical data are collected in each center.


Eligibility Criteria:
Inclusion Criteria:

* kidney transplant recipients
* at least 18 years
* admitted to hospital for CAP. Non-inclusion criteria were:

Exclusion Criteria:

* incomplete CAP definition
* hospital-acquired pneumonia
* another diagnosis explaining the symptoms
* patients with non-functional kidney graft
Role of Steroids and Extended Scorpion Anti-Venom Use in Cardiac Affection Among Scorpion Stung Pediatric Cases

Scorpion envenomation is considered a serious public health issue in the Middle East and Northern Sahara . According to the world health organization (WHO), around 1.2 to 1.5 million individuals are suspected to scorpion stings annually in Middle East; with 3000 to 5000 deaths rate .

In Egypt, the percent of scorpion cases was 1.6% of all patients presented to Ain Shams University Poison Control Center during 2019.Initially within 1-2 hours of sting hypotension and bradycardia are encountered followed by hypotension and tachycardia between 4 and 48 hours due to severe left ventricular dysfunction and hypotension alone with good volume pulse and warm extremities is observed later in the recovery stage.

Cardiopulmonary problems such pulmonary edema and/or cardiogenic shock are the key characteristics of severe cases.Myocardial ischemia, release of catechol amines, and the direct impact of scorpion venom on cardiac fibers are the main three explanations to these cardiac complications.

Inflammation is one of the key processes involved in the pathogenesis. Neurotoxins can cause the release of inflammatory mediators. Increased pulmonary vascular permeability following the release of inflammatory mediators, such as platelet activating factor, leukotrienes, and prostaglandins had been suggested to explain the development of cardiogenic pulmonary edema.

Troponin is the biomarker of choice for the detection of cardiac injury. Cardiac troponin I (cTnI) isoform is predominant in myocardial tissue .Increased serum levels of pro-inflammatory cytokines, interleukins and tumor necrosis factor alpha had also been observed in many experimental studies following scorpion envenomation in plasma and in rat lungs respectively and on humans.

Scorpion Anti-Venom has a significant role in life saving of stung patients, but there is still a conflict about the duration of its administration mainly after occurrence of myocardial toxicity in stung patients. Corticosteroids are known to decrease the level of inflammatory mediators produced during the process of inflammation including cytokines. Dexamethasone is steroid with powerful anti-inflammatory effect that works by calming down body's immune response to reduce pain, itching and swelling .

Eligibility Criteria:
Inclusion Criteria:

- Patients with scorpion stings and diagnosed as grade 1, 2 \& 3 (according to recent history of scorpion sting and clinical presentation at the time of admission) .

Exclusion Criteria:

* Patients with history of cardiac disease, OR previous cardiac operation and or previous abnormal cardiac investigations .
* Patients with history of chronic renal, hepatic, chest or CNS diseases .
* Patients with chronic inflammatory diseases such as auto-immune diseases, with chronic use of corticosteroids .
* Envenomated cases that are described as grade 4 scorpion envenomation.
* Cases of scorpion sting above age of 18 years.
Fractional Laser Versus Radiofrequency in Androgenetic Alopecia

Patients with Androgenetic alopecia will be randomized into 2 groups; Group FCO2 receiving Fractional CO2 or Group FRF receiving Fractional Microneedling Radiofrequency.

Group FCO2 will be to receiving fractional CO2 to one randomized side of the scalp, and Group FRF will be receiving Fractional Microneedling radiofrequency to one randomized side of the scalp.

All patients will receive 4 sessions with 4-week intervals.each session will be followed by immediate topical application of 6 puffs (=1 mL) of minoxidil 5% solution twice daily and also in between the sessions and during follow up period

Eligibility Criteria:
Inclusion Criteria:

* • both genders are included.

  * Patients above 18 years old.

Exclusion Criteria:

* • Patients with patchy hair loss.

  * Patients with Telogen Effluvium or diffuse alopecia areata.
  * Patients with cicatricial alopecias.
  * Patients with associated inflammatory scalp disorders such as psoriasis or seborrheic dermatitis.
  * Patients with collagen vascular disorders.
  * Prior use of topical steroids on scalp in the previous 2 weeks.
  * Prior use of systemic steroids in the previous 1 month.
Improvement in Postoperative Pain Outcomes

This is an observational study project aims at improving postoperative pain outcomes by evaluating the current status of postoperative pain managements in the institution. Then the investigators will compare the results by internal and external benchmarking. Then they will suggest recommendations to improve the current situation of postoperative pain management.

At least half of the patients suffer from moderate to severe post-operative pain. The price of poorly managed pain is high: pain impedes recovery, causes suffering and prolongs the hospital stay. PAIN OUT provides tools for measurement, feedback and benchmarking of pain treatment quality in order to improve patient care. A research project that aims at improving postoperative pain treatment outcomes by evaluating the current status of postoperative pain managements in our institution. Then the investigators compare the results by internal and external benchmarking. Then suggest recommendations to improve the current situation of postoperative pain management.

parameters include" Patient's data Pain assessments by using the visual analogue score of 11 point (from "0" no pain - "10" worst pain) will be evaluated as the following: Worst pain since surgery, Least pain since surgery, Pain score at rest. Pain score during movements in bed, Pain score during deep breathing and coughing, How often the severe pain since surgery (%), Does the pain interfere with sleeping pattern, and the side effects.

Eligibility Criteria:
Inclusion Criteria:

* Postoperative patients during the first 24 hours of surgery (day 1)
* Male and Females
* Adults

Exclusion Criteria:

* Patient refusal
* Drug abusers and addicts
* Major significant systemic diseases
* Language barriers
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined regimen.

Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).

Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).

Patients receive ddI alone for 4 weeks, followed by 8 weeks of combination ddI/ribavirin. Patients who complete the first 12 weeks without major toxicity may receive an additional 12 weeks of combination therapy on an optional basis. Patients are followed for 60 days after the last treatment visit.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Stable maintenance or prophylaxis therapy for opportunistic infection, if such therapy was administered for at least 30 days prior to study entry.
* Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis.
* Fluconazole for mucosal candidiasis or cryptococcosis.
* Acyclovir (up to 1.0 g/day).
* Dapsone.
* Ketoconazole.
* Quinolones.
* Tetracycline.
* Vitamins and herbal therapies.
* Antibiotics as clinically indicated.
* Systemic corticosteroids for \< 21 days for acute problems.
* Regularly prescribed medications.

Patients must have:

* HIV positivity by ELISA confirmed by Western blot.
* CD4 count \< 500 cells/mm3 within 30 days prior to study entry.
* No active opportunistic infections requiring treatment (patients on stable maintenance and prophylaxis therapy for opportunistic infections for at least 30 days are permitted).

NOTE:

* Enrollment of women is encouraged.

Prior Medication:

Allowed:

* Prior stable maintenance or prophylaxis therapy for opportunistic infection, if administered for at least 30 days prior to study entry.

Exclusion Criteria

Concurrent Medication:

Excluded:

* Concurrent rifampin or rifabutin.
* Other anti-HIV drugs and investigational agents.
* Biological response modifiers.
* Ganciclovir or foscarnet.
* Systemic cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

* Concurrent radiation therapy other than limited localized therapy to the skin.

Patients with the following prior conditions are excluded:

* History of peripheral neuropathy.
* History of pancreatitis or active liver disease.

Prior Medication:

Excluded:

* Prior ddI.
* Ribavirin within 60 days prior to study entry.
* AZT or ddC within 2 weeks prior to study entry.

Prior Treatment:

Excluded:

* Transfusion within 2 weeks prior to study entry.

Active alcohol abuse.
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter

The objective of this feasibility study is to demonstrate the safety and feasibility of using an investigational extracorporeal system and catheter to filter hemorrhagic cerebrospinal fluid (CSF) post subarachnoid hemorrhage (SAH) treatment, and reintroduce the CSF via the same catheter.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18 years or older
* Informed consent by the patient or his/her legally authorized representative
* Modified Fisher Grade 2, 3, or 4
* Hunt \& Hess I-III
* First aneurysmal SAH that has been confirmed by Angio, CTA or MRA
* Patient is ≤ 48 hours post bleeding event
* World Federation of Neurosurgeons (WFNS) Grades I-IV and those Grade V patients who improve to Grade IV or less after ventriculostomy.

Exclusion Criteria:

* Patients with a SAH due to mycotic aneurysm or AV malformation
* Patients who present with an acute MI or unstable angina
* Patients with uncontrolled diabetes
* Patients who present with a creatinine \> 2.0mg/dl
* Imaging demonstrates supratentorial mass lesions greater than 50 cc
* Imaging demonstrates more than 5 mm of mid-line-shift associated with infarction and or edema
* Effacement of the basilar cisterns (suprasellar, ambient, chiasmatic and quadrageminal)
* Vasospasm on admission as defined by angiographic evidence
* Patients with a coagulopathy that cannot be reversed per the professional discretion of the investigator
* Thrombocytopenia def. platelet count \< 100,000
* Patients on low molecular weight heparin e.g., Lovenox
* Patients on Clopidogrel bisulfate (Plavix) or other chronic platelet inhibitors
* Patients with a documented history of cirrhosis
* Patients who will be managed with supportive care rather than intervention
* Obstructive hydrocephalus i.e., non-communicating
* Pregnancy
* History of posterior fusion hardware that would interfere with placement of the catheter
* Pre-existing Lumbar Drain
* Local skin infections or eruptions over the puncture site
* Signs of systemic infection/sepsis or pneumonia
* Lumbar puncture within 6 hours
* Concurrent participation in another study which is not observational or retrospective in nature without prior approval from the Sponsor
Soy Nuts and Cardiovascular Risk in Postmenopausal Women

To determine the effect of a whole soy food, dietary soy nuts, on blood pressure, lipid levels, inflammation and menopausal symptoms in postmenopausal women.

The present study examines the effect of a whole soy food, soy nuts (dry roasted soybeans), added to the Therapeutic Lifestyle Change diet on blood pressure, lipids, inflammation and menopausal symptoms in postmenopausal hypertensive and normotensive women in a randomized crossover trial during an 8-week period. We sought to determine whether dietary soy had an additional benefit to the currently recommended heart healthy diet.

Eligibility Criteria:
Inclusion Criteria:

* Women with absence of menses for at least 12 months or irregular periods and hot flashes.

Exclusion Criteria:

* were current cigarette smoking or smoking in the previous year;
* clinical coronary artery disease, peripheral artery disease, or cerebrovascular disease;
* known diabetes mellitus or a fasting glucose level of 126 mg/dL or greater;
* a history of breast cancer; a fasting triglyceride level greater than 400 mg/dL; systolic BP of 165 mm Hg or greater or diastolic BP of 100 mm Hg or greater;
* untreated hypothyroidism; systemic or endocrine disease known to affect lipid, mineral, or bone metabolism;
* and consumption of more than 21 alcoholic drinks per week.
* Use of lipid-lowering drugs, hormone therapy, medications for osteoporosis, and soy products was discontinued for 2 months before entering the study. Participants took a multivitamin but no additional vitamin or mineral supplements or other soy products during the study.
Effects of Massage Therapy on Peripheral Neuropathy and Quality of Life

The aim of this randomized controlled experimental study was to determine the effect of massage applied to colorectal cancer patients receiving chemotherapy on peripheral neuropathy and quality of life.

The aim of this randomized controlled experimental study was to determine the effect of massage applied to colorectal cancer patients receiving chemotherapy on peripheral neuropathy and quality of life.Investigation was carried out between February 2012- May 2013 with 52 patients meeting study criteria and receiving chemotherapy in Akdeniz University outpatient chemotherapy unit (28 study group, 24 control).

Massage therapy group:The experimental group patients were given a series of effleurage, petrissage and surface fraction types of classical massage on local parts of they're body-below, elbow-frontal arm-hand (20 minutes) and below knee-leg (lower part)-foot (20 minutes) two days of treatment of 16 times total.The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.Baseline, patient characteristics , peripheral neuropathy symptoms, neuropathic pain, cancer and chemotherapy-related symptoms, and quality of life were completed. Peripheral neuropathy symptoms, cancer, and chemotherapy-related symptoms were assessed at each cycle (2th, 4th, 6th, 8th,10th,12th,14th, 16th. week- (two-week intervals)). Neuropathic pain and quality of life were measured at 4, 10, and 16 weeks. At week 16 (2 weeks after the intervention), the grade of peripheral sensory neuropathy was determined.

Control Group: The patients received routine care. Baseline, patient characteristics , peripheral neuropathy symptoms, neuropathic pain, cancer and chemotherapy-related symptoms, and quality of life were completed. Peripheral neuropathy symptoms, cancer, and chemotherapy-related symptoms were assessed at each cycle (2th, 4th, 6th, 8th,10th,12th,14th, 16th. week (two-week intervals)). Neuropathic pain and quality of life were measured at 4, 10, and 16 weeks. At week 16 (2 weeks after the intervention), the grade of peripheral sensory neuropathy was determined.

Eligibility Criteria:
Inclusion Criteria:

* over 18 years old
* have a diagnosis of colorectal cancer
* receiving FOLFOX-4 chemotherapy protocol
* to receive a maximum of 4 cycles of FOLFOX-4 chemotherapy
* platelet values over -100.000/mm3
* no obstacle to massage application

Exclusion Criteria:

* previously been diagnosed with polyneuropathy,
* has been diagnosed with diabetes,
* is addicted to alcohol,
* has been amputated at the extremities,
* has a skin infection and skin integrity disorder,
* has megaloblastic anemia, uses anticoagulants,
* takes drugs that hide or affect neuropathy findings
* has had massage therapy within the last month.
Enamel Matrix Derivative in Non-surgical Periodontal Treatment

The aim of the study is to investigate the effect of enamel matrix derivative in addition to scaling and root planing in comparison to scaling and root planing only in periodontitis patients that have already undergone initial periodontal therapy and are in periodontal maintenance.

Enamel matrix derivative (EMD) have already been widely applied as a regenerative bio-modulator in periodontal surgery and have been demonstrated to enhance periodontal regeneration. Recently, also its flapless, non-surgical application has been shown to have beneficial effects when applied during initial therapy of periodontitis.

The present study is designed as a single-blinded randomized controlled clinical trial. We plan to include a total of 50 periodontitis patients that have already undergone initial periodontal therapy, but still show remaining sites with increased periodontal probing depth (PPD). Patients will be randomly allocated at a 1:1 ratio to either scaling and root planing (SRP) in combination with EMD application into the affected pockets (test group, n=25) or to SRP only (control group, n=25). Before treatment, as well as after 3, 6 and 12 months, we plan to assess site-specific periodontal parameters as well as whole-mouth oral hygiene indices. Furthermore, we intend to evaluate gingival crevicular fluid, as well as parameters representing periodontal disease activity.

Eligibility Criteria:
Inclusion Criteria:

* Periodontitis stage III
* Patients that have completed initial periodontal therapy, and have remaining periodontal pockets of ≥6mm up to 9mm PPD
* Given written informed consent form for participation in the study

Exclusion Criteria:

* Systemic antibiotics within the previous 3 months
* Pregnant or breastfeeding women
* Any current or past clinically significant pathology/disease (comorbidity) that, in the opinion of the periodontists, might confound the results or poses an additional risk to the subject during participation in the study, such as renal insufficiency, malignancy, rheumatoid osteoarthritis, human immunodeficiency syndrome.
* Patients with at least one tooth of mobility grade 0 or 1 and/or furcation involvement grade 0 or I according to Hamp
Chinese EOPD Registry

The purpose of the Chinese Early-onst Parkinson's disease Registry (CEOPDR) is to develop a database of persons with early-onset Parkinson's disease (EOPD) in China.

Parkinson's disease (PD) is the second most common disorder among degenerative neurological disease. Early-onset PD (EOPD) has its unique clinical feature and genetic basis.Investigators aim to establish a database of EOPD,and characterize the clinical feature, genetic basis, environmental factors and their interactions EOPD in China.

Method:

1. Clinical feature will be measured by scales and neurological tests.Standard scales includes: Unified Parkinson's Disease Rating Scale(UPDRS), Hoehn-Yahr stages, NMSS, MMSE, PDSS(Parkinson disease sleep scales),Rapid Eye Movement Sleep Behaviour Disorder Questionnaire(RBDQ-HK),ESS(Epworth Sleepiness Scale),Rome III functional constipation scale，SCOPA-AUT (the Scale for Outcomes in PD for Autonomic Symptoms)，PFS(Parkinson Fatigue Scale)，CH-RLSq，Hyposmia rating scale(HRS)HAMILT depression scale，the 39-item Parkinson's Disease Questionnaire(PDQ-39)，Freezing of gait scale(FOG)，dyskinesia related scales, Wearing-off scale(WO)
2. Peripheral blood from patients was collected for whole exome sequencing.
3. The environmental factors are explored by questionnaires including smoking,drinking, pesticide and heavy metals.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with PD by UKBB and other standard criteria Age of onset is no more than 50 years old.

Exclusion Criteria:

* Patients have a family history of PD.